Error loading player: No playable sources found
5390
AGA FDA Town Hall
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
This session was jointly developed by AGA and representatives from the Division of Gastroenterology at the FDA Center for Drug Evaluation and Research. This session will give health care professionals and clinical trialists a chance to hear directly from FDA representatives about the agency's thinking behind the most recent product approvals and guidance documents impacting the GI community. The 2023 session will address new therapies for IBD, EoE, and C. difficile infection, as well as the agency's current thinking on artificial intelligence-enabled medical devices.
This session was jointly developed by AGA and representatives from the Division of Gastroenterology at the FDA Center for Drug Evaluation and Research. This session will give health care professionals and clinical trialists a chance to hear directly from FDA representatives about the agency's thinking behind the most recent product approvals and guidance documents impacting the GI community. The 2023 session will address new therapies for IBD, EoE, and C. difficile infection, as well as the agency's current thinking on artificial intelligence-enabled medical devices.
Moderators
University of Tennessee Health Science Center
Middleburg Consultants
Related Products
AGA Diet-Driven Gut Microbiome Dynamics, Metabolism and Extinction
This session showcases the pioneering work done by the MMT section mentor awardee Dr. Justin Sonnenburg and his mentees who are leading independent programs focused on the intersection of diet-microbe-host physiology…
AGA Small Intestinal Microbiome: An Underappreciated Driver of Gastrointestinal Disease and Novel Therapeutic Target
Microbiome science in the gut has focused on the study of colonic, and more frequently, fecal communities. While the upper gastrointestinal tract has significantly lower bacterial density than the colon, it still harbors a dynamic microbial community…
AGA The Mucosal Immune Response and Nonimmune Cells in IBD
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
AGA Aryl Hydrocarbon Receptor in Gastrointestinal Disease
The role of nutrition and the microbiome is evident in IBD and functional bowel disorders. The microbiome can affect the way nutrients are metabolized in bioactive components. It is of important to understand the molecular sensors of such metabolized components…
